Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05383742
Other study ID # A5384
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date December 7, 2023
Est. completion date May 10, 2027

Study information

Verified date March 2024
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact ACTG Clinicaltrials.gov Coordinator
Phone (301) 628-3348
Email ACTGCT.gov@fstrf.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare a 6-month regimen of high-dose rifampicin (RIF), high-dose isoniazid (INH), linezolid (LZD), and pyrazinamide (PZA) versus the World Health Organization (WHO) standard of care (SOC) treatment for tuberculosis meningitis (TBM).


Description:

Rationale: TBM is a devastating illness with high risk of mortality and severe neurologic morbidity. Although recent data suggest that significant dose increases in RIF may improve outcomes in TBM, mortality remains high, and enhanced treatment strategies are needed. In addition, limited data are available to guide treatment duration in adults with TBM. The overall goal of this Phase II, randomized, open-label trial is to assess the PK, safety, and longitudinal treatment outcomes of an optimized 6-month regimen of high-dose RIF, high-dose INH, LZD, and PZA to the WHO 9-month SOC regimen for the treatment of TBM. Primary objective: To determine if a regimen of high-dose RIF, high-dose INH, LZD, and PZA improves functional outcomes measured by the modified Rankin Scale (mRS) at 48 weeks compared with WHO SOC for the treatment of TBM. Design: Participants with definite, probable, or possible TBM will be randomized to one of the two study arms below and randomization will be stratified by HIV status and stage of disease as defined by the modified BMRC criteria. Arm A: RIF 35 mg/kg + INH 15 mg/kg + LZD 1200 mg + PZA 25 mg/kg for 2 weeks, followed by RIF 35 mg/kg + INH 10 mg/kg + LZD 1200 mg + PZA 25 mg/kg for 6 weeks, and then RIF 35 mg/kg and INH 10 mg/kg for 16 weeks, for a total of 24 weeks of study treatment. Arm B: WHO SOC: RIF 10 mg/kg + INH 5 mg/kg + EMB 20 mg/kg + PZA 25 mg/kg for 8 weeks, followed by RIF 10 mg/kg and INH 5 mg/kg for 28 weeks, for a total of 36 weeks of study treatment. Up to 15 mg/kg or a maximum of 900 mg daily of oral RIF will be permitted in this arm at clinician's discretion. All participants in Arms A and B will receive pyridoxine, while receiving INH, and adjunctive corticosteroids according to disease severity for at least 6 weeks. All participants in Arms A and B will be followed from randomization to week 72. Procedures: Study visits will include interval history, blood collection for laboratory testing, peripheral neuropathy screening, visual acuity, color vision, and contrast sensitivity visual testing to monitor for AEs. Lumbar puncture will be performed for assessments of CSF microbiology, LAM and other biomarkers. Optional collection and storage of blood and storage of remaining CSF for future testing will occur. Urine will be obtained for LAM assessment. Plasma and CSF PK assessments will be performed. Participants will undergo assessment of functional status with the mRS and WHO DAS 2.0. Participants will also be assessed with a neurocognitive battery and depression questionnaire (PHQ-9).


Recruitment information / eligibility

Status Recruiting
Enrollment 330
Est. completion date May 10, 2027
Est. primary completion date May 10, 2027
Accepts healthy volunteers No
Gender All
Age group 15 Years and older
Eligibility Inclusion Criteria: - Definite, probable, or possible TBM diagnosis wherein the participant is being committed to a full course of SOC anti-TB treatment for TBM in the setting of routine care. CSF, imaging, laboratory, and other results used to determine definite, probable, or possible TBM can be from testing performed as part of routine care, as long as obtained within 21 days prior to study entry - Persons aged =15 years - Absence of HIV-1 infection, as documented by any licensed rapid HIV test or HIV-1 enzyme or chemiluminescence immunoassay (E/CIA) test kit, within 30 days prior to study entry, OR - HIV-1 infection, documented by any licensed rapid HIV test or HIV-1 E/CIA test kit at any time prior to entry and confirmed by a licensed Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen or plasma HIV-1 RNA viral load. Two or more HIV-1 RNA viral loads of >1,000 copies/mL are also acceptable as documentation of HIV-1 infection, or documentation of HIV diagnosis in the medical record by a healthcare provider - Documentation within 3 days prior to study entry of stage of disease using BMRC TBM grade: - Grade I: Glasgow Coma Score 15, no focal neurological deficits - Grade II: Glasgow Coma Score 11-14 or 15 with focal neurological deficits - Grade III: Glasgow Coma Score =10 - The following laboratory values obtained within 3 days prior to study entry: - Serum creatinine =1.8 times upper limit of normal (ULN) - Hemoglobin =8.0 g/dL for men, =7.5 g/dL for women - Absolute neutrophil count =600/mm3 - Platelet count =60,000/mm3 - Alanine aminotransferase (ALT) =3 x ULN - Total bilirubin =2 x ULN - For participants of reproductive potential who have not been post-menopausal for at least 24 consecutive months (i.e., no menses within the preceding 24 months), or participants who have not undergone surgical sterilization, hysterectomy, bilateral salpingectomy, bilateral oophorectomy, or tubal ligation, documentation of a serum or urine pregnancy test result (positive or negative; see protocol for test sensitivity requirement) within 21 days prior to study entry - Participants with documentation of a positive pregnancy test will be consented using the consent form for pregnant participants. Participants of reproductive potential with documentation of a negative pregnancy test must agree to use at least one acceptable form of contraception, or abstain from sexual activity that could lead to pregnancy while receiving study treatment and for 30 days after stopping study treatment. Participants who are not of reproductive potential or whose partner(s) has documented azoospermia are not required to use contraception. Any statement of self-reported sterility or that of the partner's must be entered in the source documents - Ability and willingness of participant or parent or legally authorized representative (for adolescents or participants unable to provide consent) to provide informed consent/assent - Ability to comply with the protocol requirements in the opinion of the site investigator Exclusion Criteria: - More than 14 cumulative days of first-line TB medications, including but not limited to INH, RIF, EMB, and PZA, received within 90 days prior to study entry - Known current or previous drug resistant TB infection (i.e., resistance to one or more first-line TB medications, including but not limited to INH, RIF, EMB, LZD and PZA) - Known allergy/sensitivity or any hypersensitivity to components of study TB drugs (INH, RIF, LZD, PZA, and EMB) or their formulation - For participants who are able to undergo the Brief Peripheral Neuropathy Screen (BPNS) within 21 days prior to study entry, Grade 3 subjective peripheral neuropathy score on the BPNS AND EITHER vibratory loss OR absent ankle jerks - Expected concomitant use or use up to 21 days prior to study entry of monoamine oxidase inhibitors or selective serotonin reuptake inhibitors, or concomitant use of any other drug with significant interaction with the study drugs (See protocol) - For participants with HIV and ART-naïve, planned initiation of ART during the first 4 weeks after randomization - For participants with HIV and on ART that includes a protease inhibitor, nevirapine, or other prohibited ART (see protocol), contraindication to switching to an acceptable alternative regimen (e.g., efavirenz, high-dose raltegravir or dolutegravir with nucleoside reverse transcriptase inhibitors, as per local SOC) prior to randomization. TB treatment, including study drugs, should be started as soon as possible - Contraindication to LP at discretion of treating clinician (e.g., unequal pressures between intracranial compartments due to mass lesion, non-communicating hydrocephalus) - Positive cryptococcal antigen, gram stain, bacterial culture, or other test result obtained from a CSF specimen collected within 21 days prior to entry as part of routine care indicating CNS infection with a pathogen other than Mtb (e.g., cryptococcal meningitis, bacterial meningitis).

Study Design


Intervention

Drug:
Rifampicin (RIF)
Rifampicin 35 mg/kg
Isoniazid (INH)
Isoniazid 10 or15 mg/kg
Linezolid (LZD)
1200 mg
Pyrazinamide (PZA)
25 mg/kg
ethambutol (EMB)
20 mg/kg
Rifampicin
10 mg/kg
Isoniazid
5 mg/kg

Locations

Country Name City State
Brazil Hospital Nossa Senhora da Conceicao CRS (12201) Porto Alegre
Brazil Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS (12101) Rio De Janeiro
India Byramjee Jeejeebhoy Government Medical College (BJMC) CRS (31441) Pune
Kenya Moi University Clinical Research Center (MUCRC) CRS (12601) Eldoret
Kenya Kenya Medical Research Institute/Walter Reed Project Clinical Research Center (KEMRI/WRP) CRS (12501) Kericho
Malawi Malawi CRS Lilongwe
Mexico Nutrición-Mexico CRS Mexico City
Peru Barranco CRS Lima
Philippines De La Salle Health Science Institute Angelo King Medical Research Center (DLSHSI-AKMRC) (Site ID: 31981) Cavite
South Africa Durban International CRS Durban
South Africa University of the Witwatersrand Helen Joseph (WITS HJH) CRS Johannesburg
Tanzania Kilimanjaro Christian Medical Centre (KCMC) (Site ID: 5118) Moshi
Thailand Siriraj Hospital, Mahidol University NICHD CRS (Site ID: 5115) Bangkok Bangkoknoi
Thailand Chiangrai Prachanukroh Hospital NICHD CRS Chiang Mai
Vietnam National Lung Hospital CRS (Site ID: 32483) Vinh Phúc Hanoi
Zimbabwe Milton Park CRS Harare

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Countries where clinical trial is conducted

Brazil,  India,  Kenya,  Malawi,  Mexico,  Peru,  Philippines,  South Africa,  Tanzania,  Thailand,  Vietnam,  Zimbabwe, 

Outcome

Type Measure Description Time frame Safety issue
Other Proportion of participants who relapsed by 12 and 24 weeks after completion of study treatments At week 12 and 24
Other Positive or negative CSF Xpert Ultra At Day 3, week 2 and week 8
Other Positive or negative CSF and urine LAM At Day 3, weeks 2, 8 and 12
Other Change in sterilization of CSF culture At Weeks 2 and 6-8
Other Change in CSF white blood cell count At Weeks 2 and 6-8
Other Change in CSF glucose At Weeks 2 and 6-8
Other Change in CSF blood glucose ratio At Weeks 2 and 6-8
Other Change in CSF protein At Weeks 2 and 6-8
Primary Modified Rankin Scale (6-death, 5-severe disability, 4-moderately severe disability, 3-moderate disability, 2-slight disability, 1-no significant disability, 0-no symptoms) At 48 Weeks
Secondary Modified Rankin Scale (all 7 levels) At weeks 12,24,36 and 72
Secondary Modified Rankin Scale using collapsed categories at 12, 24, 36, 48 and 72 weeks: mRS (0 or 1), (2 or 3), (4 or 5), (6) 12, 24, 36, 48 and 72 weeks
Secondary Modified Rankin Scale 5 or 6 At 12, 24, 36, 48 and 72 weeks
Secondary Change in mRS from baseline to each of 12, 24, 36, 48, and 72 weeks At 12, 24, 36, 48, and 72 weeks
Secondary Time to death over 48 and 72 weeks At weeks 48 and 72
Secondary Proportion of participants with Grade 3 or higher AEs over 8 weeks At 8 weeks
Secondary Proportion of participants with a serious adverse event (SAE) over 8 weeks At 8 weeks
Secondary Proportion of participants who complete study treatments, which is defined as completing 168 doses within 185 days for Arm A and 252 doses in 278 days for Arm B At day 185 and day 278
Secondary Proportion of participants with TBM IRIS (as defined in protocol) over 48 weeks At week 48
Secondary Wechsler Adult Intelligence Scale Digit Symbol or Symbol Digit Modalities Neurocognitive battery performance At week 24 and 48
Secondary Color Trails 1, 2 Neurocognitive battery performance At week 24 and 48
Secondary Category Fluency Neurocognitive battery performance At week 24 and 48
Secondary Hopkins Verbal Learning Test-Revised Neurocognitive battery performance At week 24 and 48
Secondary Grooved Pegboard Bilateral Neurocognitive battery performance At week 24 and 48
Secondary Finger-tapping Bilateral Neurocognitive battery performance At week 24 and 48
Secondary Patient Health Questionnaire (PHQ-9) total score defined as Glasgow Coma Score of 15 for =48 hours for hospitalized participants over 4 weeks At 24, 48, and 72 weeks
Secondary WHO DAS score defined as Glasgow Coma Score of 15 for =48 hours for hospitalized participants over 4 weeks At 24, 48, and 72 weeks
Secondary Change in BMRC TBM grade at week 1. BMRC TBM grade is defined as: Grade I: Glasgow Coma Score 15, no focal neurological deficits
Grade II: Glasgow Coma Score 11-14 or 15 with focal neurological deficits
Grade III: Glasgow Coma Score =10
At week 1
Secondary Time to coma clearance, which is defined as Glasgow Coma Score of 15 for =48 hours for hospitalized participants, over 4 weeks. At week 4
Secondary Time to new neurological event, which is defined as fall in Glasgow Coma Score of =2 points for =48 hours for hospitalized participants or since last visit for non-hospitalized participants, new onset seizures, new focal neurologic deficit At week 48
Secondary CSF to plasma ratio At Day 3, Week 2, 6 or 8
Secondary Rate of CSF uptake At Day 3, Week 2, 6 or 8
Secondary Plasma absorption rate constant (ka) At Day 3, Week 2, 6 or 8
Secondary Drug clearance (Cl/F) At Day 3, Week 2, 6 or 8
Secondary Volume of distribution (Vd) At Day 3, Week 2, 6 or 8
Secondary Post-hoc Bayesian predictions of secondary parameters Cmax At Day 3, Week 2, 6 or 8
Secondary Time to Cmax At Day 3, Week 2, 6 or 8
Secondary Time to AUC0-24 At Day 3, Week 2, 6 or 8
Secondary Time to plasma elimination half-life At Day 3, Week 2, 6 or 8
Secondary Time to CSF elimination half-life At Day 3, Week 2, 6 or 8
See also
  Status Clinical Trial Phase
Completed NCT01371916 - Diagnosis of Tuberculous Meningitis by ESAT-6 in CSF N/A
Active, not recruiting NCT00433719 - Immediate Versus Deferred Antiretroviral Therapy for HIV-Associated Tuberculous Meningitis N/A
Completed NCT02237365 - A Pilot Study of Adjunctive Aspirin for the Treatment of HIV Negative Adults With Tuberculous Meningitis Phase 2
Not yet recruiting NCT02588196 - The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis Phase 4
Completed NCT03092817 - Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial) Phase 3
Recruiting NCT03787940 - Optimizing Antituberculosis Therapy in Adults With Tuberculous Meningitis N/A
Not yet recruiting NCT05917340 - Intensified Short Course Regimen for TBM in Adults Phase 3
Completed NCT01802502 - Rifampicin Explorative PK Study for Tuberculous Meningitis Comparing Oral and Intravenous Preparation Phase 2
Recruiting NCT05636254 - Diagnostic Accuracy of Imaging Findings in TBM/Spinal Tubercular Arachnoiditis and Correlation With Outcomes
Recruiting NCT03898635 - Retrospective Real-word Study of Linezolid for the Treatment of Tuberculous Meningitis
Completed NCT05781646 - Xpert MTB/RIF Assay for Diagnosis of Tuberculous Meningitis (TBM) in Maharaj Nakorn Chiang Mai Hospital N/A
Active, not recruiting NCT03100786 - Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis Phase 3
Recruiting NCT04145258 - Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis Phase 3
Completed NCT03226379 - Driving Reduced AIDS-associated Meningo-encephalitis Mortality N/A
Recruiting NCT05590455 - Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis Phase 2
Recruiting NCT04308928 - Evaluation of New Biomarker-based Approaches for Improving the Diagnosis of Childhood Tuberculous Meningitis